Related Experiment Video
Updated: Jun 2, 2026
08:49
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
Published on: May 11, 2018
Ventricular assist system applications in end-stage heart failure.
1Department of Cardiovascular Surgery, Ege University Medical Faculty, Izmir, Turkey.
Transplantation Proceedings
|April 14, 2011
Summary
Ventricular assist devices (VADs) offer a promising treatment for end-stage heart failure, serving as a bridge to transplant or destination therapy. This study shows acceptable outcomes with VADs, highlighting potential for improved results with technological advancements.
Area of Science:
- Cardiology
- Cardiac Surgery
- Biomedical Engineering
Background:
- Mechanical circulatory support is crucial in managing end-stage heart failure.
- Ventricular assist devices (VADs) are utilized for patients awaiting transplantation or unsuitable for it.
- This report details the application of VAD systems in end-stage heart failure patients.
Purpose of the Study:
- To evaluate the application and outcomes of mechanical circulatory support in patients with end-stage heart failure.
- To assess the role of VADs as a bridge-to-transplantation or destination therapy.
Main Methods:
- A cohort of 37 patients with end-stage heart failure (including 5 children) received mechanical circulatory support between April 2007 and September 2010.
- Paracorporeal pneumatic VADs were implanted in 29 patients, while axial flow pumps supported the left ventricle in 8 patients.
- Biventricular support was provided to 9 patients due to severe preoperative conditions.
Main Results:
- Heart transplantation was performed in 16 patients (43%).
- Eleven patients (30%) remained on pump support, and one patient was weaned due to recovery.
- Mortality occurred in 9 patients (24%), with multiorgan failure being the most common cause.
Conclusions:
- Ventricular assist device therapy for end-stage heart failure, as bridge-to-transplantation or destination therapy, demonstrates acceptable mortality rates.
- VADs represent a promising therapeutic option for individuals with advanced heart failure.
- Further advancements in device technology, anticoagulation monitoring, and clinical expertise are expected to improve outcomes.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...